Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what”…

Allegri, Ricardo

doi:10.1590/1980-57642020dn14-030005

Cited by 13 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their early identification is crucial, but still today, it is challenging. CSF biomarkers represent precious tools for assessing neurodegenerative disorders providing in vivo information on the underlying pathology [ 21 , 22 , 23 , 24 ]. Specifically, CSF is an ideal biofluid due to its proximity to the brain parenchyma, the moderately low cost in comparison to positron emission tomography imaging, and the safety of lumbar puncture.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

Agnello

Sasso

Vidali

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: Alpha-synuclein (α-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of α-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) α-syn levels in several neurological disorders; (2) Methods: We measured CSF α-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer’s Disease (AD), cerebrovascular diseases, inflammatory central nervous system diseases, other neurological diseases, Parkinson’s Disease (PD), and peripheral neuropathy; (3) Results: Patients with PD showed the lowest and patients with AD the highest levels of CSF α-syn (1372 vs. 2912 pg/mL, respectively, p < 0.001). In AD patients, α-syn levels were significantly associated with tau proteins; (4) Conclusions: α-syn could represent a biomarker of neurodegenerative diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

Agnello

Sasso

Vidali

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Neurodegenerative diseases are an important health burden and their early identification is crucial, but this is still challenging today. CSF biomarkers represent precious tools for assessing neurodegenerative disorders, providing in vivo information on the underlying pathology [ 23 , 24 , 25 , 26 , 27 ]. Specifically, CSF is an ideal biofluid due to its proximity to the brain parenchyma, the lower intrinsic protease activity than blood, the moderately low cost in comparison to positron emission tomography (PET) imaging and the safety of lumbar puncture.…”

Section: Discussionmentioning

confidence: 99%

Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

et al. 2021

View full text Add to dashboard Cite

(1) Background: Neurogranin is a post-synaptic protein expressed in the neurons of the hippocampus and cerebral cortex. It has been recently proposed as a promising biomarker of synaptic dysfunction, especially in Alzheimer’s disease (AD). However, more efforts are needed before introducing it in clinical practice, including the definition of its reference interval (RI). The aim of the study was to establish the RI of cerebrospinal fluid (CSF) neurogranin levels in controls and individuals with non-neurodegenerative neurological diseases; (2) We included a total of 136 individuals that were sub-grouped as follows: AD patients (n = 33), patients with non-neurodegenerative neurological diseases (n = 70) and controls (33). We measured CSF neurogranin levels by a commercial ELISA kit. CSF RI of neurogranin was calculated by a robust method; (3) Results: AD patients showed increased levels of neurogranin. We also found that neurogranin was significantly correlated with T-tau, P-tau and mini mental state examination in AD patients. The lower and upper reference limits of the RI were 2.9 (90%CI 0.1–10.8) and 679 (90%CI 595–779), respectively; (4) Conclusion: This is the first study establishing the RI of CSF neurogranin.

show abstract

“…The cognitive proteinopathy field 27 has predominantly focused on imaging targets involved in the neurodegenerative process. Tau PET imaging is undoubtedly the best choice for the differential diagnosis of PD/DLB and other forms of atypical parkinsonism (see Fig 3B ).…”

Section: Advances In Radiopharmaceuticalsmentioning

confidence: 99%

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Verger

Grimaldi

Ribeiro

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

The early differential diagnosis of Parkinson disease and atypical parkinsonism is a major challenge. The use of single photon emission computed tomography (SPECT)/positron emission tomography (PET) molecular imaging to investigate parkinsonism is a fast-developing field. Imaging biomarker research may potentially lead to more accurate disease detection, enabling earlier diagnosis and treatment. This review summarizes recent SPECT/PET advances in radiopharmaceuticals and imaging technologies/analyses that improve the diagnosis of neurodegenerative parkinsonism. We are currently witnessing a turning point in the field. Integrating molecular imaging as a diagnostic technique represents an opportunity to reassess the strategies for diagnosing neurodegenerative parkinsonism.

show abstract

Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what”…

Cited by 13 publications

References 29 publications

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast‐Developing Field

Contact Info

Product

Resources

About